文献速递肝病消化道肿瘤与早癌

PRDM8通过靶向NAP1L1对肝细胞癌发挥抗肿瘤作用

PRDM8 exhibits antitumor activities toward hepatocellular carcinoma by targeting NAP1L1.
PubMed 文献 · Hepatology · 2018-05-21

PRDM8在肝细胞癌中表达下调且与较短的无复发生存期相关;过表达与敲低实验显示PRDM8抑制肝癌细胞增殖、迁移和侵袭,引起G1/S期细胞周期阻滞并诱导凋亡;体内肿瘤模型证实其抗肿瘤作用;机制上PRDM8通过调控NAP1L1抑制PI3K/AKT/mTOR信号通路。

要点

  • PRDM8在肝细胞癌中表达下调,且与较短的无复发生存期相关。
  • PRDM8抑制肝癌细胞增殖、迁移和侵袭,引起G1/S期细胞周期阻滞并诱导凋亡。
  • PRDM8通过调控NAP1L1抑制PI3K/AKT/mTOR信号通路,是肝癌治疗的潜在靶点。

核心结论

  • PRDM8作为一种功能性肿瘤抑制因子在肝细胞癌中频繁下调;通过调控NAP1L1,PRDM8抑制肝细胞癌中的PI3K/AKT/mTOR信号;PRDM8是肝细胞癌治疗的潜在靶点。

研究设计与样本

  • 研究采用慢病毒介导的过表达和敲低方法,并建立体内肿瘤模型,检测PRDM8对肝细胞癌细胞的增殖、迁移、侵袭、细胞周期和凋亡的影响,并探讨其机制。

主要发现

  • PRDM8在肝细胞癌中表达下调,且与较短的无复发生存期相关。
  • PRDM8抑制肝细胞癌细胞的增殖、迁移和侵袭。
  • PRDM8引起G1/S期细胞周期阻滞并诱导凋亡。
  • 体内肿瘤模型证实PRDM8对肝细胞癌生长和转移具有抗肿瘤作用。
  • 机制上,PRDM8通过调控NAP1L1抑制PI3K/AKT/mTOR信号通路。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hepatocellular carcinoma (HCC) is a major leading cause of cancer mortality worldwide. PRDI-BF1 and RIZ homology domain containing 8 (PRDM8) is a key regulator in neural development and testis steroidogenesis; however, its role in liver carcinogenesis remains to be investigated. In this study, PRDM8 was found to be down-regulated in HCC, which was linked with shorter recurrence-free survival. Lentiviral-based overexpression and knockdown approaches showed that PRDM8 inhibited HCC cell proliferation, migration, and invasion. PRDM8 caused G1/S cell cycle arrest and induced apoptosis. An in vivo tumor model confirmed the antitumor role of PRDM8 in HCC growth and metastasis. Mechanistic study showed that PRDM8 suppressed the PI3K/AKT/mTOR signaling cascade through the regulation of nucleosome assembly protein 1-like 1 (NAP1L1). Conclusion: PRDM8 as a functional tumor suppressor is frequently down-regulated in HCC. Through regulating NAP1L1, PRDM8 inhibits PI3K/AKT/mTOR signaling in HCC. PRDM8 is a potential target for therapies of HCC. (Hepatology 2018).

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Chen Z, Gao W, Pu L, et al. PRDM8 exhibits antitumor activities toward hepatocellular carcinoma by targeting NAP1L1. Hepatology. 2018. PMID: 29572888. doi:10.1002/hep.29890

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。